Cargando…

PARP-1 Expression Influences Cancer Stem Cell Phenotype in Colorectal Cancer Depending on p53

Poly(ADP-ribose) polymerase-1 (PARP-1) is a protein involved in multiple physiological processes. Elevated PARP-1 expression has been found in several tumours, being associated with stemness and tumorigenesis. In colorectal cancer (CRC), some controversy among studies has been described. In this stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puentes-Pardo, Jose D., Moreno-SanJuan, Sara, Casado, Jorge, Escudero-Feliu, Julia, López-Pérez, David, Sánchez-Uceta, Paula, González-Novoa, Paula, Gálvez, Julio, Carazo, Ángel, León, Josefa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002521/ https://www.ncbi.nlm.nih.gov/pubmed/36902215 http://dx.doi.org/10.3390/ijms24054787

Ejemplares similares

Agomelatine, a Melatonin-Derived Drug, as a New Strategy for the Treatment of Colorectal Cancer
por: Moreno-SanJuan, Sara, et al.
Publicado: (2023)

Narrow Leafed Lupin (Lupinus angustifolius L.) β-Conglutin Seed Proteins as a New Natural Cytotoxic Agents against Breast Cancer Cells
por: Escudero-Feliu, Julia, et al.
Publicado: (2023)

Endothelin-1 as a Mediator of Heme Oxygenase-1-Induced Stemness in Colorectal Cancer: Influence of p53
por: Ríos-Arrabal, Sandra, et al.
Publicado: (2021)

Heme Oxygenase-1 in Gastrointestinal Tract Health and Disease
por: Puentes-Pardo, Jose D., et al.
Publicado: (2020)

Core Circadian Clock Proteins as Biomarkers of Progression in Colorectal Cancer
por: Aroca-Siendones, María I., et al.
Publicado: (2021)

Circadian Genes as Therapeutic Targets in Pancreatic Cancer
por: García-Costela, María, et al.
Publicado: (2020)

In Patients With Obesity, the Number of Adipose Tissue Mast Cells Is Significantly Lower in Subjects With Type 2 Diabetes
por: Lopez-Perez, David, et al.
Publicado: (2021)

AA-NAT, MT1 and MT2 Correlates with Cancer Stem-Like Cell Markers in Colorectal Cancer: Study of the Influence of Stage and p53 Status of Tumors
por: Casado, Jorge, et al.
Publicado: (2017)

Human adipose tissue as a major reservoir of cytomegalovirus-reactive T cells
por: Redruello-Romero, Anaïs, et al.
Publicado: (2023)

In Obese Patients With Type 2 Diabetes, Mast Cells in Omental Adipose Tissue Decrease the Surface Expression of CD45, CD117, CD203c, and FcϵRI
por: Lopez-Perez, David, et al.
Publicado: (2022)

Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
por: Yélamos, José, et al.
Publicado: (2020)

An Overview of the Polymorphisms of Circadian Genes Associated With Endocrine Cancer
por: Morales-Santana, Sonia, et al.
Publicado: (2019)

Cancer Imprints an Increased PARP-1 and p53-Dependent Resistance to Oxidative Stress on Lymphocytes of Patients That Later Develop Alzheimer's Disease
por: Salech, Felipe, et al.
Publicado: (2018)

Técnicas de caracterización de polímeros /
por: Llorente Uceta, Miguel Ángel
Publicado: (1991)

53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
por: Hong, Ruoxi, et al.
Publicado: (2016)

Protective role of p53 in skin cancer: Carcinogenesis studies in mice lacking epidermal p53
por: Page, Angustias, et al.
Publicado: (2016)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

MUTYH, an adenine DNA glycosylase, mediates p53 tumor suppression via PARP-dependent cell death
por: Oka, S, et al.
Publicado: (2014)

MUTYH, an adenine DNA glycosylase, mediates p53 tumor suppression via PARP-dependent cell death
por: Oka, S, et al.
Publicado: (2015)

Erratum to: 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
por: Hong, Ruoxi, et al.
Publicado: (2016)

Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer
por: Qiu, Wei-Gang, et al.
Publicado: (2017)

Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers
por: Freire Boullosa, Laurie, et al.
Publicado: (2023)

DNA2 Nuclease Inhibition Confers Synthetic Lethality in Cancers with Mutant p53 and Synergizes with PARP Inhibitors
por: Folly-Kossi, Helena, et al.
Publicado: (2023)

Correction: Protective role of p53 in skin cancer: Carcinogenesis studies in mice lacking epidermal p53
por: Page, Angustias, et al.
Publicado: (2017)

PARP-1 and p53 Regulate the Increased Susceptibility to Oxidative Death of Lymphocytes from MCI and AD Patients
por: Salech, Felipe, et al.
Publicado: (2017)

Differential regulation of breast cancer bone metastasis by PARP1 and PARP2
por: Zuo, Hao, et al.
Publicado: (2020)

Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1
por: Hsu, En-Chi, et al.
Publicado: (2020)

Resistance to PARP-Inhibitors in Cancer Therapy
por: Montoni, Alicia, et al.
Publicado: (2013)

An update on PARP inhibitors for the treatment of cancer
por: Benafif, Sarah, et al.
Publicado: (2015)

The Nucleolus and PARP1 in Cancer Biology
por: Engbrecht, Marina, et al.
Publicado: (2020)

PARP inhibitor combinations in prostate cancer
por: Pezaro, Carmel
Publicado: (2020)

PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020)

PARP and PARG inhibitors in cancer treatment
por: Slade, Dea
Publicado: (2020)

PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

Advances in PARP Inhibitors for Prostate Cancer
por: Tisseverasinghe, Steven, et al.
Publicado: (2023)

PARP inhibitors in metastatic prostate cancer
por: Taylor, Amy K., et al.
Publicado: (2023)

PARP inhibitors as a radiosensitizer: a future promising approach in prostate cancer?
por: Angel, Martin, et al.
Publicado: (2021)

Association between PSCA, TNF-α, PARP1 and TP53 Gene Polymorphisms and Gastric Cancer Susceptibility in the Brazilian Population
por: Dantas, Roberto Nery, et al.
Publicado: (2020)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer
por: Ma, Hanlin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7r0udo4qjq4iuifj48fqbke2de